ESR1 and breast carcinoma: As their name implies, they have the interesting capacity to be antagonist or agonist of the ERs in a tissue-specific manner; for example, tamoxifen is an antagonist of ERα in the mammary gland and breast cancer cells, but is an agonist in other peripheric tissues, such as the bone, thus limiting adverse side-effects of estrogen blockade throughout the whole body39.